当前位置：
X-MOL 学术
›
N. Engl. J. Med.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Intensive Blood-Pressure Control in Patients with Type 2 Diabetes.
The New England Journal of Medicine ( IF 96.2 ) Pub Date : 2024-11-16 , DOI: 10.1056/nejmoa2412006 Yufang Bi,Mian Li,Yan Liu,Tingzhi Li,Jieli Lu,Peng Duan,Fengmei Xu,Qijuan Dong,Ailiang Wang,Tiange Wang,Ruizhi Zheng,Yuhong Chen,Min Xu,Xiaohu Wang,Xinhuan Zhang,Yanbo Niu,Zhiqiang Kang,Chunru Lu,Jing Wang,Xinwen Qiu,An Wang,Shujing Wu,Jingya Niu,Jingya Wang,Zhiyun Zhao,Huanfeng Pan,Xiaohua Yang,Xiaohong Niu,Shuguang Pang,Xiaoliang Zhang,Yuancheng Dai,Qin Wan,Shihong Chen,Qidong Zheng,Shaoping Dai,Juan Deng,Leshan Liu,Guixia Wang,Huiqi Zhu,Weidong Tang,Haixia Liu,Zhenfang Guo,Guang Ning,Jiang He,Yu Xu,Weiqing Wang,
The New England Journal of Medicine ( IF 96.2 ) Pub Date : 2024-11-16 , DOI: 10.1056/nejmoa2412006 Yufang Bi,Mian Li,Yan Liu,Tingzhi Li,Jieli Lu,Peng Duan,Fengmei Xu,Qijuan Dong,Ailiang Wang,Tiange Wang,Ruizhi Zheng,Yuhong Chen,Min Xu,Xiaohu Wang,Xinhuan Zhang,Yanbo Niu,Zhiqiang Kang,Chunru Lu,Jing Wang,Xinwen Qiu,An Wang,Shujing Wu,Jingya Niu,Jingya Wang,Zhiyun Zhao,Huanfeng Pan,Xiaohua Yang,Xiaohong Niu,Shuguang Pang,Xiaoliang Zhang,Yuancheng Dai,Qin Wan,Shihong Chen,Qidong Zheng,Shaoping Dai,Juan Deng,Leshan Liu,Guixia Wang,Huiqi Zhu,Weidong Tang,Haixia Liu,Zhenfang Guo,Guang Ning,Jiang He,Yu Xu,Weiqing Wang,
BACKGROUND
Effective targets for systolic blood-pressure control in patients with type 2 diabetes are unclear.
METHODS
We enrolled patients 50 years of age or older with type 2 diabetes, elevated systolic blood pressure, and an increased risk of cardiovascular disease at 145 clinical sites across China. Patients were randomly assigned to receive intensive treatment that targeted a systolic blood pressure of less than 120 mm Hg or standard treatment that targeted a systolic blood pressure of less than 140 mm Hg for up to 5 years. The primary outcome was a composite of nonfatal stroke, nonfatal myocardial infarction, treatment or hospitalization for heart failure, or death from cardiovascular causes. Multiple imputation was used for missing outcome data, with an assumption that the data were missing at random.
RESULTS
Of 12,821 patients (6414 patients in the intensive-treatment group and 6407 in the standard-treatment group) enrolled from February 2019 through December 2021, 5803 (45.3%) were women; the mean (±SD) age of the patients was 63.8±7.5 years. At 1 year of follow-up, the mean systolic blood pressure was 121.6 mm Hg (median, 118.3 mm Hg) in the intensive-treatment group and 133.2 mm Hg (median, 135.0 mm Hg) in the standard-treatment group. During a median follow-up of 4.2 years, primary-outcome events occurred in 393 patients (1.65 events per 100 person-years) in the intensive-treatment group and 492 patients (2.09 events per 100 person-years) in the standard-treatment group (hazard ratio, 0.79; 95% confidence interval, 0.69 to 0.90; P<0.001). The incidence of serious adverse events was similar in the treatment groups. However, symptomatic hypotension and hyperkalemia occurred more frequently in the intensive-treatment group than in the standard-treatment group.
CONCLUSIONS
Among patients with type 2 diabetes, the incidence of major cardiovascular events was significantly lower with intensive treatment targeting a systolic blood pressure of less than 120 mm Hg than with standard treatment targeting a systolic blood pressure of less than 140 mm Hg. (Funded by the National Key Research and Development Program of the Ministry of Science and Technology of China and others; BPROAD ClinicalTrials.gov number, NCT03808311.).
更新日期：2024-11-16
京公网安备 11010802027423号